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A B S T R A C T
Background: Plasma or urinary metanephrines are recommended for screening of pheochromocytomas and
paragangliomas (PPGLs). Measurements of urinary free rather than deconjugated metanephrines and additional
measurements of methoxytyramine represent other developments. For all measurements there is need for re-
ference intervals.
Methods: Plasma free, urinary free and urinary deconjugated O-methylated catecholamine metabolites were
measured by LC-MS/MS in specimens from 590 hypertensives and normotensives. Reference intervals were
optimized using data from 2,056 patients tested for PPGLs.
Results: Multivariate analyses, correcting for age and body surface area, indicated higher plasma and urinary
metanephrine in males than females and sex differences in urinary normetanephrine and free methoxytyramine
that largely reflected body size variation. There were positive associations of age with plasma metabolites, but
negative relationships with urinary free metanephrine and methoxytyramine. Plasma and urinary normeta-
nephrine were higher in hypertensives than normotensives, but differences were small. Optimization of re-
ference intervals using the data from patients tested for PPGLs indicated that age was the most important
consideration for plasma normetanephrine and sex most practical for urinary metabolites.
Conclusion: This study clarifies impacts of demographic and anthropometric variables on catecholamine meta-
bolites, verifies use of age-specific reference intervals for plasma normetanephrine and establishes sex-specific
reference intervals for urinary metabolites.
1. Introduction
Current guidelines for the biochemical diagnosis of pheochromo-
cytomas and paragangliomas (PPGLs) stipulate measurements of
plasma or urinary normetanephrine and metanephrine (together
termed metanephrines) as first-line screening tests [1]. At lower levels
of evidence, liquid chromatographic methods are recommended over
other methods of measurement and for the plasma test blood should be
drawn in the supine position [1]. There has been some debate con-
cerning the latter recommendation, this based largely on inconvenience
to clinical staff and added costs of supine sampling [2–4]. Nevertheless,
accumulating evidence supports both the advantages of liquid
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chromatography with tandem mass spectrometry (LC-MS/MS) over
immunoassay measurements and the importance of supine sampling for
optimal diagnostic accuracy of the plasma test [5–8].
Although supine blood sampling is clearly important for ensuring
high diagnostic accuracy of the plasma test, many laboratories use re-
ference intervals determined from blood samples drawn in the seated
position [9–12]. Reported upper cut-offs from seated measurements of
plasma normetanephrine, up to two times above those for supine
sampling, are too high to reliably exclude PPGLs. There is thus need for
reliable reference intervals for the plasma test determined for blood
collected in the recommended supine position. Since with seated sam-
pling the plasma test offers no diagnostic advantage over urinary
fractionated metanephrines [6,13], the urine test may be preferable for
those centers where sampling blood in the fully recumbent supine po-
sition is not possible [14]. For this and other reasons measurements of
urinary fractionated metanephrines will likely remain important.
Metanephrines in urine are commonly measured after an acid hy-
drolysis step that converts the large proportion of sulfate-conjugated
metabolites to free metabolites [15,16]. The sulfate-conjugates are
different metabolites from the free metanephrines and are produced by
a sulfotransferase enzyme located primarily in the gastrointestinal tract
where most of the sulfate-conjugated metabolites are formed [17,18].
In contrast, the single largest tissue source of the free metabolites is the
adrenal medulla or in patients with PPGLs, the tumor cells themselves
[19,20]. This offers diagnostic advantages for measurements of free
versus deconjugated metanephrines in both plasma and urine [21,22].
Sample preparation is also simpler and there are less problems with the
validity of quality assurance procedures for measurements of urinary
free than deconjugated metabolites [14,16,23]. Consequently some la-
boratories have moved to measurements of the free metabolites in urine
[23–25]. This is now made relatively simple by availability of highly
sensitive LC-MS/MS instruments, but is hindered by lack of established
reference intervals. Apart from the need for reference intervals for ur-
inary free metanephrines there is also increasing need for reliable re-
ference intervals for both plasma and urinary methoxytyramine, which
at least for plasma measurements shows utility for identification of
dopamine-producing PPGLs [26,27].
Recognising the aforementioned needs, the present analysis outlines
results for plasma free, urinary free and urinary deconjugated O-me-
thylated catecholamine metabolites determined by LC-MS/MS in spe-
cimens collected from 590 volunteers. In addition to impact of age,
gender and anthropometric variables we also assessed the importance
of considering the presence or absence of hypertension. To assess po-
tential impact of different cut-offs on diagnostic performance we ex-
amined their utility using publically available data for a population of
2,056 patients tested for PPGLs [22]. This population also served to
further validate and refine reference intervals.
2. Materials and methods
2.1. Subjects
Subjects for the reference interval population included 590 volun-
teers, aged 18 to 82 years (median 42), including 329 females and 261
males among whom 110 (33%) of the females and 129 (49%) of the
males had hypertension (Table 1). Enrolment of subjects was facilitated
by advertisement with a small financial renumeration for time. All
subjects underwent a standard medical history and physical examina-
tion that included recordings of prescribed and non-prescribed medi-
cations and dietary supplements, body weight, height, heart rate and
office blood pressure, the latter recorded in triplicate. Presence of hy-
pertension was established by systolic blood pressure above or equal to
140mmHg or diastolic blood pressure above or equal to 90mmHg and
further confirmed or excluded in 437 subjects by 24 hour ambulatory
blood pressure monitoring (systolic blood pressure ≥ 130 and diastolic
blood pressure ≥80). Hypertension was also defined in patients with a
stated history of high blood pressure controlled by antihypertensive
medications. To facilitate comparisons for other laboratories the data
from the reference population are made available in the supplement to
this report.
Data and details about the 2056 patients tested for PPGLs under a
multicenter prospective clinical protocol are provided elsewhere [22].
In brief, tumors were confirmed in 236 patients and excluded in the
other 1,860 patients. All volunteers and patients provided written in-
formed consent under protocols approved by Ethics committees at
participating centers.
2.2. Blood and urine samples
All blood sampling in volunteers was carried out between 8:00-
10:00 AM after an overnight fast and refraining from caffeinated bev-
erages in the morning before sampling, which was carried out after a
minimum of 20 minutes of supine rest. Heparinized blood samples were
kept chilled and centrifuged within 2 hours of collection to separate
plasma, which was stored at -80oC until assayed. Collections of 24-hr
urine specimens were initiated after discarding the first void upon
awakening in the morning and continuing until collection of the first
void upon awakening the next morning. Collections were returned to
the laboratory on the final day of the collection. As outlined previously
[28], metanephrines in urine are relatively stable and samples were not
acidified in order to avoid deconjugation at low pH. Completeness of
collections was assessed by volume and 24-hr creatinine outputs, with
subjects asked to perform repeat collections in cases of questionable
results. Blood sampling and urine collections in patients tested for
PPGLs were carried out according to similar standard-operating pro-
cedures used for volunteers.
2.3. LC-MS/MS
LC-MS/MS was performed using a QTRAP 5500 triple quadrupole
mass spectrometer (AB Sciex, Darmstadt, Germany) coupled to an
Acquity® ultra performance liquid chromatography system (Waters
Corporation, Milford, MA, USA). The methods for analysis of plasma
and urinary metabolites are detailed elsewhere [28,29], including
modifications for measuring plasma methoxytyramine [30]. To facil-
itate comparisons of data from this report with measurements by other
laboratories, data are provided from the results of an international
inter-laboratory proficiency program [31]; for this comparison, mea-
surements of those metabolites have been compared to medians of
other participating laboratories (Supplemental figures 1 & 2)
2.4. Data analyses
Statistical analyses utilized the JMP statistics software package (SAS
Institute Inc, Cary, NC). Differences between men and women or be-
tween hypertensives and normotensives were initially assessed using
the Wilcoxon test. Associations of body surface area were assessed since
larger body size in males than females (Table 1) was hypothesized to
contribute to higher urinary outputs of catecholamine metabolites in
males than females. Similarly, differences between normotensives and
hypertensives were hypothesized to be influenced by the predominance
of male sex and advanced age in hypertensives than normotensives.
Therefore, impacts of sex, blood pressure status, age and body surface
area on plasma and urinary catecholamine metabolites were subse-
quently assessed by least squares multivariate analyses.
Further analyses to validate or refine reference intervals utilized
publically available data for a population of 2,056 patients tested for
PPGLs [22]. Influences of sex on proportions of false-positive versus
true-negative results were assessed by application of both sex-specific
and non-specific upper cut-offs of 97.5 and 99.5 percentiles derived
from the reference population. Impact of body size on proportions of
false-positive versus true-negative results were similarly assessed using
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height and body mass data available in 1,248 patients without PPGLs
who were divided into three equally sized groups according to dis-
tributions of body surface area. Similarly, to assess need for age-specific
upper cut-offs, patients in whom PPGLs were excluded were divided
into three equal age-groups and differences in proportions of false-po-
sitive results examined between groups; assessments included ex-
amination of age-specific upper cut-offs according to a previously es-
tablished equation [32]. The various combinations of upper cut-offs
were also applied to the group of 236 patients with PPGLs to establish
those that provided optimal diagnostic performance. Results of diag-
nostic performance according to cut-offs derived from the reference
population and optimized using the patient population were compared
to results using cut-offs derived from the Youden index (maximal value
of sensitivity + specificity – 1) for ROC curves of each of the three
metabolites in the three test panels [33].
3. Results
3.1. Sex
Plasma concentrations of normetanephrine did not differ between
males and females, whereas plasma concentrations of metanephrine
and methoxytyramine were respectively 29% and 14% higher
(P< 0.0001) in males than females (Figure 1 A-C). Urinary outputs of
free and deconjugated metabolites were all consistently higher
(P< 0.0001) in males than females (Figure 1 D-I). Largest differences
were observed for urinary free and deconjugated metanephrine; these
were respectively 39% and 42% higher in males than females compared
to 21% and 27% differences for free and deconjugated normeta-
nephrine and 22% and 37% differences for methoxytyramine.
Higher plasma concentrations in males than females for plasma
metanephrine and methoxytyramine remained significant (P< 0.0001)
after multivariate correction for age, body surface area and hyperten-
sion (Table 2); however, leverage plots indicated larger differences for
metanephrine with than without correction (46% versus 29%). Simi-
larly, an influence of sex on urinary outputs of metanephrine remained
significant (P<0.0001) after multivariate analysis with leverage plots
indicating 45-46% higher mean outputs of free and deconjugated me-
tanephrine in males than females.
In contrast to metanephrine, differences between males and females
for urinary outputs of free normetanephrine and methoxytyramine
disappeared after multivariate analysis (Table 2), this reflecting sig-
nificant (P< 0.0001) positive relationships of urinary outputs with
body surface area that was larger in males than females (Table 1).
Similarly, although still higher (P<0.002) in males than females after
correction for body surface area (Table 2), magnitudes of differences
were diminished from 27% to 14% for urinary deconjugated normeta-
nephrine and from 37% to 28% for methoxytyramine.
3.2. Age
Age showed a positive relationship with plasma concentrations of
normetanephrine (rs=0.3260, P<0.0001) and weaker positive re-
lationships with plasma metanephrine (rs=0.1418, P=0.0006) and
methoxytyramine (rs=0.1991, P<0.0001). Positive relationships of
the three O-methylated metabolites with age remained significant after
multivariate analysis (Table 2). There were no relationships of age with
either urinary outputs of free or deconjugated normetanephrine or with
deconjugated metanephrine and methoxytyramine. However, age
showed significant weak negative relationships with urinary free me-
tanephrine (rs=-0.2058, P< 0.0001) and methoxytyramine (rs=-
0.1996, P<0.0001). Similar results were observed after multivariate
analyses (Table 2).
3.3. Hypertension
Hypertensives had 17% higher (P< 0.0001) plasma concentrations
of normetanephrine and 14% and 22% higher (P<0.0005) respective
urinary outputs of free and deconjugated normetanephrine than nor-
motensives (Figure 2 A,D,G). Among other O-methylated metabolites,
hypertensives showed slightly higher plasma concentrations of plasma
metanephrine (P< 0.05) and methoxytyramine (P<0.005) than nor-
motensives (Figure 2, B,C), but no differences for urinary free or de-
conjugated metanephrine and methoxytyramine (Figure 2, E,F,H,I).
With multivariate analysis the differences for plasma metanephrine
and methoxytyramine between hypertensives and normotensives dis-
appeared, whereas those for plasma as well as urinary free and de-
conjugated normetanephrine remained significant (Table 2). Never-
theless, leverage plots indicated that differences between hypertensives
and normotensives were reduced to only 4%, 7% and 13% higher va-
lues for plasma, urinary free and urinary deconjugated normeta-
nephrine respectively.
3.4. Impact of sex-specific reference intervals on false-positive results
As expected the 97.5 and 99.5 percentiles for plasma concentrations
of free normetanephrine differed little between the two sexes (Table 3).
Nevertheless, among the 1820 patients tested for PPGLs in whom
Table 1
Demographic, anthropometric and urinary volume and creatinine data for the subjects of the reference population
Normotensives (NT) Hypertensives (HT) NT vs HT
Gender Males Females Males Females P-value
N 132 219 129 110 <0.0001
Age (yr) 31 34 51 52 <0.0001
(18-81) (18-71) (18-81) (23-82) HT>NT
Height (m) 1.80** 1.68 1.79** 1.67 0.6116
(1.62-1.97) (1.50-1.84) (1.65-2.01) (1.49-1.80)
Weight (kg) 81** 66 90** 70 <0.0001
(59-133) (46-112) (61-151) (50-139) HT>NT
BSA (m2) 1.95** 1.69 1.98** 1.75 < 0.0001
(1.61-2.46) (1.34-2.25) (1.62-2.55) (1.36-2.40) HT>NT
BMI (kg/m2) 24.5* 23.3 27.6* 25.6 < 0.0001
(18.2-42.0) (17.0-43.6) (19.6-50.4) (17.6-50.4) HT>NT
24 hr Urine Volume (L) 2.00 1.90 2.04 1.84 0.3989
(0.54-4.05) (0.46-4.80) (0.80-4.68) (0.50-3.86)
Urine Creatinine (mmol/day) 15.6** 10.3 15.2** 9.4 0.4522
(4.1-32.2) (3.6-21.1) (5.3-32.9) (2.3-18.3)
Data are shown as medians and ranges. * P<0.01, **P< 0.0001 higher in males than females for either normotensive or hypertensive groups. Abbreviations: BSA,
body surface area; BMI, body mass index.
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disease was excluded, females showed a slightly higher (P=0.0368)
proportion of false-positive results than males for plasma normeta-
nephrine at the 97.5 percentile-derived cut-offs and a nearly 2-fold
higher (P=0.0099) proportion at the 99.5 percentile-derived cut-offs
(Table 4); differences lost significance with application of sex-specific
97.5 percentile-derived cut-offs but remained significant (P=0.0103)
with sex-specific 99.5 percentile-derived cut-offs.
In contrast to normetanephrine, although plasma concentrations of
metanephrine and methoxytyramine were higher (P<0.0001) in males
than females (Figure 1 & Table 2), there were no significant differences
in proportions of false-positive results for either metabolite between
males and females with and without application of sex-specific upper
cut-offs (Table 4).
Without sex-specific upper cut-offs, measurements of urinary free
metabolites showed substantially higher proportions of false-positive
results in males than females compared to plasma measurements
(Table 4), this reflecting the large impacts of sex on urinary free me-
tabolites (Table 3). False-positive results for all three urinary free me-
tabolites were 3.3- to 7.0-fold higher (P<0.03) with use of both 97.5
and 99.5 percentile-derived cut-offs in males than females. With sex-
specific 97.5 percentiles there were no differences between males and
females in proportions of false-positive results for urinary free meta-
bolites; however, with application of sex-specific 99.5 percentiles there
remained a slightly higher (P=0.0220) proportion of false-positive
results for urinary free normetanephrine.
There was a smaller impact of sex on proportions of false-positive
results for urinary deconjugated than for the free metabolites (Table 4).
Without adjustment for sex, proportions of false-positive results using
the 97.5 percentiles were 1.9- to 2.3-fold higher (P< 0.0001) in males
than females for urinary deconjugated normetanephrine and meta-
nephrine and 2.1-fold higher (P=0.0036) for methoxytyramine. After
application of sex-specific upper cut-offs there were no differences in
Fig. 1. Plasma free (A,B,C), urinary free (D,E,F) and urinary deconjugated (G,H,I) normetanephrine (NMN, A,D,G), metanephrine (MN, B,E,H) and methoxytyramine
(MTY, C,F,I) in females (F) versus males (M) of the reference population. Data are shown as dot, box and whisker plots with whiskers showing the 90, 97.5 and 99.5
percentiles with ranges at limits.
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false-positive results for metanephrine and methoxytyramine, whereas
the difference for normetanephrine was reversed to a 1.6-fold higher
(P=0.0047) proportion of false-positives in females than males. Re-
versals in proportions of false-positive results between males and fe-
males with and without sex-specific cut-offs were further exaggerated
with application of the 99.5 percentiles for both urinary deconjugated
normetanephrine and methoxytyramine; however, for urinary decon-
jugated metanephrine the 2.7-fold higher (P=0.0017) proportion of
false-positives without sex-specific cut-offs disappeared after applica-
tion of sex-specific cut-offs.
3.5. Association of body surface area with false-positive results
Larger body surface area was associated with lower (P<0.01)
proportions of false-positive results for plasma normetanephrine using
both 97.5 and 99.5 percentile-derived upper cut-offs (Supplemental
Table 1). This impact of body surface area on false-positives for plasma
normetanephrine remained significant (P<0.05) with use of sex-spe-
cific cut-offs and gained significance (P=0.0002) for metanephrine
with use of the 97.5 but not 99.5 percentile-derived cut-offs.
In contrast to plasma normetanephrine, larger body surface area
was associated with increased (P< 0.0001) proportions of false-posi-
tive results for urinary free and deconjugated normetanephrine with
use of 97.5 percentile-derived upper cut-offs (Supplemental Table 1).
Increased body surface area was also associated with increased
(P< 0.005) proportions of false-positive results for urinary free and
deconjugated metanephrine and urinary free methoxytyramine. With
sex-specific upper cut-offs, the association of body surface area with
false-positive results for urinary metabolites was diminished, but re-
mained significant (P< 0.05) for urinary free and deconjugated nor-
metanephrine.
3.6. Age-specific reference intervals
False-positive results for plasma normetanephrine increased
(P< 0.0001) with advancing age such that patients over 60 years of
age had 3.5- and 4.3-fold higher proportions of false-positive results
than patients under 45 years at respective 97.5 and 99.5 percentile-
derived upper cut-offs (Supplemental Table 2). With use of age-specific
cut-offs, calculated according to a previously described equation [32],
the impact of advancing age on proportions of false-positive results was
reversed. With these age-specific cut-offs the overall proportion of false-
positive results for plasma normetanephrine was 4.7% compared to
11.0% and 2.8% for respective use of 97.5 and 99.5 percentile-derived
cut-offs.
Advancing age was associated with an increased rate of false-posi-
tive results for plasma metanephrine (P=0.0028) with use of 97.5 but
not 99.5 percentile-derived upper cut-offs and had no impact on rates of
false positives for methoxytyramine (Supplemental Table 2). Apart
from a small reduction in false-positive results for urinary free norme-
tanephrine in patients over 60 years of age, there were no other dif-
ferences in false-positive results for urinary metabolites among age
groups with use of either 97.5 or 99.5 percentile-derived upper cut-offs.
3.7. Reference versus patient groups
Patients tested for PPGLs in whom tumors were excluded were older
(P< 0.0001), more often female (P=0.0156), had a higher body mass
index (P< 0.0001) and a higher prevalence of hypertension
(P< 0.0001) than subjects of the reference group (Supplemental table
3). Accordingly they also had higher (P<0.05) plasma concentrations
and urinary outputs of nometanephrine than subjects of the reference
group, with most pronounced differences (P<0.0001) observed for
plasma free and urinary deconjugated normetanephrine. Urinary ex-
cretion of deconjugated methoxytyramine was also slightly but sig-
nificantly higher (P=0.0030) in the patient than the reference group.
Excretion of urinary free metanephrine on the other hand was higher in
the reference than the patient group.
Likelihood of false-positive results according to the 97.5 percentile-
derived cut-offs of the reference population and without adjustment for
sex was at least 2-fold higher than expected for panels of plasma free
and urinary deconjugated metabolites, but only marginally higher than
expected for the urinary free metabolites (Table 4). Multivariate ana-
lyses indicated that the presence of hypertension had negligible impact
on false-positive results for each of the three test panels (Supplemental
figure 3). The high proportion of false-positive results for the plasma
panel was also largely independent of body surface area, body mass
index and gender, but was clearly impacted by age to a similar level as
unidentified group differences in patient and reference populations.
Variations in body surface area, age and gender contributed to the high
proportion of false-positive results for urinary deconjugated metabo-
lites, but not one of these factors contributed to the likelihood of false-
positive results beyond that of unidentified group differences between
patient and reference populations. In contrast, sex was the only factor
identified to contribute to the relatively minimal increase in likelihood
of false-positive results for urinary free metabolites in the patient
compared to the reference population.
Table 2
Multivariate analysis of influences of sex, age, body surface area (BSA) and presence of hypertension on plasma concentrations of free metabolites and urinary
outputs of free and deconjugated metabolites
Amine Sex Age BSA Hypertension
Plasma free metabolites
Normetanephrine 0.2089 <0.0001 +ve 0.0022 -ve 0.0174 HT > NT
Metanephrine <0.0001 M > F 0.0045 +ve <0.0001 -ve 0.4522
Methoxytyramine <0.0001 M > F <0.0001 +ve 0.5896 0.7002
Urinary free metabolites
Normetanephrine 0.0971 0.7038 <0.0001 +ve 0.0093 HT > NT
Metanephrine <0.0001 M > F <0.0001 -ve 0.1185 0.9605
Methoxytyramine 0.1107 <0.0001 -ve <0.0001 +ve 0.4681
Urinary deconjugated metabolites
Normetanephrine 0.0019 M > F 0.8750 0.0020 +ve <0.0001 HT > NT
Metanephrine <0.0001 M > F 0.4559 0.0270 -ve 0.5056
Methoxytyramine <0.0001 M > F 0.0768 0.0195 +ve 0.9982
Data are shown as P-values. Where significant (i.e., P< 0.05) differences are shown for sex as higher in females than males (F>M) or higher in males than females
(M>F), for relationships with age or BSA according to the negative (-ve) or positive (+ve) nature of relationships and for any differences between normotensives
(NT) and hypertensives (HT). Data were normalized by logarithmic transformation before statistical analyses.
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3.8. Optimized cut-offs
With use of 97.5 percentiles as upper cut-offs for all metabolites, the
plasma test delivered high diagnostic sensitivity (99.2%), but sub-
optimal specificity with a false-positive rate of over 20% (Table 5).
With use of 99.5 percentile-derived upper-cut-offs, specificity was in-
creased to 95.1% but at a loss in diagnostic sensitivity to 94.9%. Further
improvement in overall diagnostic performance of the plasma test was
achieved using age-specific upper cut-offs for normetanephrine and
optimized cut-offs for metanephrine and methoxytyramine, this man-
ifest mainly by increased diagnostic sensitivity (97.9%) with minimal
loss of specificity (94.2%) compared to use of 99.5 percentiles.
Considerably improved diagnostic specificity of urinary tests was
achieved using sex-specific 99.5 compared to the 97.5 percentiles,
though this was associated with unacceptable loss in diagnostic sensi-
tivity to below 90% (Table 5). For urinary free metabolites, acceptable
diagnostic sensitivity of 93.4% at a specificity of 94.2% was achieved
using sex-specific 97.5 percentiles for normetanephrine and sex-specific
99.5 percentiles for methoxytyramine and metanephrine. For urinary
deconjugated metabolites diagnostic sensitivity was increased to 92.9%
at a specificity of 92.1% using adjustments to sex-specific 97.5 per-
centiles for normetanephrine, sex-specific 99.5 percentiles for meta-
nephrine and adjusted sex-specific 99.5 percentiles for methoxytyr-
amine according to the data of tables 3 and 4.
Use of cut-offs derived from ROC curves for each metabolite (i.e.,
Youden’s index), although associated with slight gains in diagnostic
sensitivity, was associated with unacceptable loss of diagnostic speci-
ficity and considerably reduced overall diagnostic performance
(Table 5).
Fig. 2. Plasma free (A,B,C), urinary free (D,E,F) and urinary deconjugated (G,H,I) normetanephrine (NMN, A,D,G), metanephrine (MN, B,E,H) and methoxytyramine
(MTY, C,F,I) in normotensives (NT) versus hypertensives (HT) of the reference population. Data are shown as dot, box and whisker plots with whiskers showing the
90, 97.5 and 99.5 percentiles with ranges at limits.
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4. Discussion
Apart from confirming the already established importance of sex-
specific reference intervals for urinary metanephrines and age-specific
reference intervals for plasma normetanephrine, the present study
provides new data for LC-MS/MS measurements of urinary free meta-
bolites and clarifies impacts of body size and blood pressure status on
all measured variables in relation to sex and age. Presumably reflecting
population differences it is further illustrated that care should be ex-
ercised in application of 97.5 percentiles in reference populations as
diagnostic cut-offs in patient populations. During testing for PPGLs,
such differences between reference and patient populations are com-
monly ascribed to presence of hypertension in the latter population.
However, as shown here presence of hypertension has relatively
minimal impacts on plasma and urinary metabolites and likelihood of
false-positive results.
As expected, false-positive results for panels of tests increased ac-
cording to numbers of tests in each panel. However, use of 97.5 per-
centile-derived cut-offs resulted in more than 2-fold higher proportions
of false-positive results for plasma free and urinary deconjugated me-
tabolites than expected if reference and patient populations had been
matched. In contrast, proportions of false-positive results for the panel
of urinary free metabolites were close to the maximum expected with
matched populations (i.e., 7.5%), supporting use of reference
population-derived cut-offs for this panel. Age was the most important
single factor identified contributing to the higher than expected pro-
portion of false-positive results for plasma metabolites, with additional
factors identified to contribute to higher than expected proportions of
false-positive results for urinary deconjugated metabolites.
Nevertheless, other differences in patient and reference populations
clearly contributed to the higher than expected proportions of false-
positive results in patient populations tested for PPGLs. Acute anxiety,
panic attacks and comorbidities in tested patient populations such as
heart failure, chronic kidney disease and obstructive sleep apnea are all
known to activate sympathetic nervous or adrenal medullary systems
[34–39] and thereby may contribute to the relatively high prevalence of
false-positive results in patient populations. Medications that alter the
disposition of catecholamines are other factors that can contribute to
false-positive results for LC-MS/MS based measurements [14]. How-
ever, patients on such medications were excluded from the patient
study population.
With the above considerations in mind it becomes apparent that use
of reference-population derived 97.5 percentiles do not always provide
an optimal method for selecting upper cut-offs. The Youden index
provides an alternative method [33], but as illustrated here a major
limitation to this approach is that such cut-offs are inappropriate for
tests involving panels of multiple analytes some of which carry more
power for disease discrimination than others. As a result, derived cut-
offs for some analytes, although optimal when used alone, are not op-
timal when used in combination. The result, as shown here with use of
Youden index-derived cut-offs, is unacceptably low diagnostic specifi-
city.
Until new mathematical algorithms are established for optimizing
cut-offs of multiple analytes in test panels it seems that the most ap-
propriate approach for reference interval optimization is to place most
weight in the analyte of a panel that provides the highest diagnostic
performance when considered alone. For the O-methylated catechola-
mine metabolites, normetanephrine provides the single most important
analyte for discrimination of patients with and without PPGLs. Thus,
use of sex-specific 97.5 percentiles for normetanephrine appeared most
appropriate for urinary panels, with a further adjustment for urinary
deconjugated normetanephrine to correct a reversal in false-positive
results. Accompanying use of the 99.5 percentiles for metanephrine and
methoxytyramine improved diagnostic specificity with minimal loss in
sensitivity and overall improved diagnostic performance. For plasma
metabolites optimal performance was obtained using age-specific re-
ference intervals for normetanephrine as established previously [32];
for metanephrine and methoxytyramine single cut-offs for males and
females that were slightly above 99.5 percentiles contributed to opti-
mized performance. Together the above considerations support use of
the cut-offs outlined here and applied in a recent study [22] as well as
part of our routine diagnostic service.
Whether the aforementioned age- and gender-specific cut-offs may
be applicable to other laboratories or whether further adjustments are
required depends on any bias of the currently described methods
compared to others. Today such bias can be assessed by participation in
inter-laboratory quality assurance programs [31], facilitated in the
present report by provision of results from one program (Supplemental
figures 1 & 2). Participation in such programs thereby provides a ve-
hicle for harmonization of reference intervals [40], which can further
benefit from availability and common use of certified reference mate-
rial.
Independent of whether the optimized cut-offs outlined here are
applicable for other laboratories, further validation is recommended.
Nevertheless, the present data do provide useful background informa-
tion for any laboratories seeking to establish or update their LC-MS/MS
measurements of plasma or urinary free metanephrines, the methods of
choice for diagnosis of PPGLs [22]. Age-specific reference intervals for
plasma normetanephrine are particularly useful for optimized diag-
nostic performance of the plasma test. Although sex is one of the more
Table 3
Medians and 97.5 and 99.5 percentiles for plasma concentrations and urinary
outputs of O-methylated catecholamine metabolites.
All Males Females
Plasma NMN (pmol/L)
Median 337 340 334
97.5 percentiles (174-676) (175-674) (173-688)
99.5 percentiles (129-953) (161-999) (118-1002)
Plasma MN (pmol/L)
Median 149 172 130
97.5 percentiles (59-312) (71-321) (52-281)
99.5 percentiles (36-371) (59-394) (28-396)
Plasma MTY (pmol/L)
Median 29 30 27
97.5 percentiles (12-60) (15-65) (8-57)
99.5 percentiles (6-90) (8-96) (5-88)
Urinary free NMN (nmol/24hr)
Median 114 127 106
97.5 percentiles (49-268) (52-280) (45-242)
99.5 percentiles (31-370) (30-410) (28-424)
Urinary free MN (nmol/24hr)
Median 89 109 78
97.5 percentiles (28-220) (39-249) (21-191)
99.5 percentiles (15-269) (30-299) (11-248)
Urinary free MTY (nmol/24hr)
Median 197 224 181
97.5 percentiles (82-475) (93-523) (75-374)
99.5 percentiles (56-563) (58-751) (38-550)
Urinary deconjugated NMN (nmol/24hr)
Median 1031 1157 929
97.5 percentiles (448-2313) (466-2708) (380-2004)
99.5 percentiles (285-3164) (412-4041) (230-2311)
Urinary deconjugated MN (nmol/24hr)
Median 531 669 447
97.5 percentiles (172-1217) (241-1333) (140-1175)
99.5 percentiles (91-1471) (191-2051) (90-1408)
Urinary deconjugated MTY (nmol/24hr)
Median 1125 1316 1004
97.5 percentiles (441-3946) (477-4179) (418-3487)
99.5 percentiles (322-6793) (338-11600) (313-5853)
Abbreviations: NMN, normetanephrine; MN, metanephrine; MTY, methox-
ytyramine
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important variables to consider for measurements of urinary metabo-
lites, the present data indicate that at least for urinary free normeta-
nephrine and methoxytyramine the higher outputs in males than fe-
males appear to largely reflect differences in body size. Higher urinary
outputs of deconjugated normetanephrine and methoxytyramine in
males than females were also impacted by body size, but for these
metabolites gender appears to have an independent influence. In con-
trast, consistently higher urinary outputs of both urinary free and de-
conjugated metanephrine, as well as plasma metanephrine in males
than females appears to be completely independent of body size. These
sex-dependent differences likely reflect the negative relationships of
epinephrine and metanephrine with both body fat and body mass index
and the higher body fat content of females than males [41].
From the above considerations it might be concluded that at least
for urinary free normetanephrine and methoxytyramine, reference in-
tervals should be tailored to body size. To make this possible, however,
height and body weight information from patients would need to be
recorded and ideally made available with laboratory requests to gen-
erate personalized reference intervals. Since the impact of body size on
false-positive urinary test results is largely negated using sex-specific
reference intervals, such reference intervals provide a more practical
and unified approach to correct for both body size and sex.
Nevertheless, body size likely remains an important variable to consider
for interpreting urinary results in specific patients who are particularly
large or small for their sex. Normalization to body size may be parti-
cularly useful for children.
In summary, this study provides information for implementation of
sex- and age-specific reference intervals for plasma and urinary O-me-
thylated metabolites particularly important for laboratories moder-
nizing to LC-MS/MS measurements that for urinary tests should now
include a shift from deconjugated to the free metabolites [22]. The data
are additionally useful for clarifying underlying factors than can impact
likelihood of false-positive results.
Table 4
Percent false-positive test results according to use of the 97.5 and 99.5 per-
centiles with and without adjustment for sex in patients tested for PPGLs
Without adjustment for sex With adjustment for sex
F M F&M F M F&M
Plasma free metabolites (n = 1820)
NMN (97.5) 12.7* 9.5 11.1 11.8 9.5 10.7
MN (97.5) 5.2 6.7 6.0 7.6 5.8 6.6
MTY (97.5) 7.2 9.8 8.5 8.4 7.9 8.1
ALL (97.5) 19.9 21.5 20.8 22.4 19.4 20.9
NMN (99.5) 3.7* 1.8 2.5 3.4* 1.5 2.5
MN (99.5) 2.3 2.6 2.5 1.5 1.9 1.7
MTY (99.5) 1.3 2.0 1.7 1.3 1.4 1.4
ALL (99.5) 6.6 5.8 6.0 5.7 4.2 4.9
Urine free metabolites (n = 1756)
NMN (97.5) 2.3 7.1*** 4.7 4.1 6.0 5.1
MN (97.5) 0.7 4.4*** 2.5 1.8 2.4 2.1
MTY (97.5) 0.7 3.3*** 2.0 3.1 1.7 2.4
ALL (97.5) 3.5 11.8*** 7.7 8.0 8.2 8.1
NMN (99.5) 0.3 1.9** 1.1 0.2 1.3* 0.7
MN (99.5) 0.3 1.7** 1.1 0.5 1.1 0.8
MTY (99.5) 0.2 1.3* 0.7 0.3 0.6 0.5
ALL (99.5) 0.9 3.7** 2.2 1.0 2.4* 1.7
Urine deconjugated metabolites (n=1757)
NMN (97.5) 6.3 11.7*** 9.0 10.4** 6.6 8.5
MN (97.5) 3.3 7.5*** 5.4 3.6 5.0 4.3
MTY (97.5) 2.4 5.1** 3.7 3.2 4.8 4.0
ALL (97.5) 10.2 20.3*** 15.3 15.1 14.1 14.6
NMN (99.5) 2.4 1.8 2.1 6.3*** 0.9 3.5
MN (99.5) 1.3 3.5** 2.4 1.7 0.9 1.3
MTY (99.5) 0.5 0.9 0.7 0.8* 0.1 0.5
ALL (99.5) 3.8 5.7 4.7 7.9*** 1.6 4.7
* P< 0.05; **P<0.005; *** P< 0.0001 higher than other gender.
Abbreviations: F, females; M, males; NMN, normetanephrine; MN, meta-
nephrine; MTY. methoxytyramine.
Table 5
Diagnosis test performance according to different selections of upper cut-offs
Cut-off selection Plasma free Urinary free Urinary deconjugated
1. 97.5 percentile - sex specific
NMN UC M, 674; F, 688 M, 280; F, 242 M, 2708; F, 2004
MN UC M, 321; F, 281 M, 249; F, 191 M, 1333; F, 1175
MTY UC M, 65; F, 57 M, 523; F, 374 M, 4179; F, 3487
Sensitivity 99.2% 94.2% 93.8%
Specificity 79.1% 92.3% 85.4%
2. 99.5 percentile - sex specific
NMN UC M, 999; F, 1002 M, 410 F, 424 M, 4041; F, 2311
MN UC M, 394; F, 396 M, 299; F, 248 M, 2051; F, 1408
MTY UC M, 96; F, 88 M, 751; F, 550 M, 11600; F, 5853
Sensitivity 94.9% 88.9% 89.4%
Specificity 95.1% 98.3% 95.3%
3. Age-specific plasma NMN*, optimized 97.5 percentiles for urinary NMN & optimized MN & MTY
NMN UC 542-1092* M, 280; F, 242 M, 2708; F, 2313
MN UC 446 M, 299; F, 248 M, 2051; F, 1408
MTY UC 107 M, 751; F, 550 M, 6793; F, 5853
Sensitivity 97.9% 93.4% 92.9%
Specificity 94.2% 94.2% 92.1%
4. Youden's-derived cut-offs - sex specific
NMN UC M, 761; F, 873 M, 346; F, 259 M, 2768; F, 2776
MN UC M, 349; F, 301 M, 264; F, 200 M, 1872; F, 997
MTY UC M, 47; F, 42 M, 318; F, 235 M, 2632; F, 1370
Sensitivity 98.7% 93.8% 95.1%
Specificity 74.0% 77.1% 75.0%
Upper cut-offs (UC) for normetanephrine (NMN), metanephrine (MN) and methoxytyramine (MTY) are shown in units of pmol/L for plasma free metabolites and
nmol/24 hr for urinary metabolites. Where specified sex-specific cut-offs are shown separately for males (M) and females (F). *Diagnostic performance of the plasma
test using age-specific upper cut-offs for NMN (UCNMN) was calculated according to the equation (UCNMN = 2.07x10-6 . age3 + 0.545) from a minimum of 542 pmol/
L at age 5 to a maximum of 1092 pmol/L at age 65 and beyond.
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